A Phase 4 interventional study of metoprolol succinate prolonged-release tablet and felodipine in Hypertension, sponsored by AstraZeneca. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2009-03-13.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
This is an open-label, non-comparative, multi-centre clinical study to evaluate the Efficacy and safety of Metoprolol Succinate prolonged-release tablet (Betaloc Zok) in patients with mild to moderate essential hypertension.
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's enrollment of 310 is above the median of 90 across 4,995 interventional studies indexed under Hypertension.
Browse Hypertension studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The patients with mild to moderate essential hypertension
Drug: metoprolol succinate prolonged-release tablet and felodipine
a regimen that starts with metoprolol succinate prolonged-release tablet 47.5mg once daily, orally and allows for dose escalation to 95mg once daily, orally at 4 weeks if not controlled; at week 8 allows for the addition of felodipine sustained release tablet 5mg once daily, orally
Also known as: Betaloc ZOK and Plendil
Percent of subjects reaching blood pressure target at wk 8 after metoprolol succinate prolonged release tablet treatment, and magnitude of systolic and diastolic blood pressure reduction from baseline among subjects who reached target (below 140/90mmHg).
Time frame: Day -7- -1, Day1, Day 28, Day 56,Day 84
The magnitude of systolic and diastolic blood pressure reduction from baseline among all the subjects at week 8 after metoprolol succinate prolonged release tablet treatment.
Time frame: Day -7- -1, Day1, Day 28, Day 56,Day 84
The percentage of subjects reaching blood pressure target at week 4, and the magnitude of systolic and diastolic blood pressure reduction from baseline among all the subjects and those subjects who reached target
Time frame: Day -7- -1, Day1, Day 28, Day 56,Day 84
The percentage of subjects reaching blood pressure target at week 12, and the magnitude of systolic and diastolic blood pressure reduction from baseline among all the subjects and those subjects who reached target
Time frame: Day -7- -1, Day1, Day 28, Day 56,Day 84
No study locations are listed for this record.
This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca